Thursday 18 April 2013

Novel AKT pathway inhibitor, ARQ 092, demonstrates safety, effective target inhibition

The researchers have confirmed that the novel oral agent ARQ 092 inhibits the AKT pathway and has a manageable safety profile in patients with a variety of advanced solid tumours. Hyperglycemia indicated effective AKT pathway inhibition, it occurred prior to dose-limiting skin toxicity and could be treated according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. Read more here.

No comments:

Post a Comment